At North American Cystic Fibrosis Conference, Beximco Pharma鈥檚 Triko, a much affordable generic version of Trikafta, was launched for cystic fibrosis patients worldwide, said a press release.
Cystic fibrosis is a rare but life threatening genetic disorder with very low life expectancy. Trikafta from US based Vertex Pharmaceuticals, is a breakthrough triple combination therapy for CF containing elexacaftor, tezacaftor, and ivacaftor which significantly improves survival rates. But it is very expensive for most people.
Under this circumstance, a group of mothers, whose children are living with CF, have launched a community-run buyers鈥� club to help patients around the world access Triko by Beximco Pharma at the conference held on October 23 in Seattle, United States.
The families announced that Beximco鈥檚 Triko will be priced at just $6,375 per child per year against the US list price of $3,70,000 for originator brand Trikafta. Triko is expected to be available for purchase and supply from Spring 2026.
Gayle Pledger, a senior organiser for Just Treatment who leads the global Right to Breathe campaign, also a CF mum from the UK, announced the launch of the Beximco Pharma鈥檚 generic Triko at NACFC.
She said, 鈥榃e鈥檝e watched children suffer and die while a treatment sat on the shelf, priced out of reach. Today, that changes, we鈥檝e proven that patient power can change what billion dollar corporations refuse to.鈥�
Triko will cost $12,750 for an adult per year and $6,375 for a child per year.
Beximco is also separately launching Bexdeco, a generic version of ivacaftor, one of the components of Triko, which costs just $5 per tablet.
Beximco Pharmaceuticals chief operation officer Rabbur Reza said, 鈥榃e understand that access to medicine for rare diseases, like CF, is restricted due to a limited number of treatment options which are prohibitively expensive. We believe our much affordable generic version of Trikafta will have a transformative impact on thousands of patients living with CF who are currently deprived of treatment due to the significant cost burden.鈥�
